(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(-0.44%) $83.48
(-1.16%) $1.619
(0.01%) $2 347.40
(0.85%) $27.49
(0.35%) $925.30
(-0.05%) $0.934
(-0.15%) $11.01
(-0.07%) $0.800
(0.00%) $92.17
1.10% $ 60.72
@ $60.49
Wydano: 26 bal. 2024 @ 20:03
Zwrot: 0.39%
Poprzedni sygnał: bal. 26 - 18:21
Poprzedni sygnał:
Zwrot: 1.30 %
Live Chart Being Loaded With Signals
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia...
Stats | |
---|---|
Dzisiejszy wolumen | 583 957 |
Średni wolumen | 865 760 |
Kapitalizacja rynkowa | 6.60B |
EPS | $0 ( 2024-02-27 ) |
Następna data zysków | ( $-1.110 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -14.67 |
ATR14 | $1.533 (2.52%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-23 | Pickering Grant | Buy | 15 000 | Common Stock |
2024-04-23 | Pickering Grant | Sell | 15 000 | Common Stock |
2024-04-23 | Pickering Grant | Sell | 15 000 | Stock Option (Right to Buy) |
2024-04-18 | Guggenhime Andrew | Sell | 8 000 | Stock Option (right to buy) |
2024-04-18 | Guggenhime Andrew | Buy | 8 000 | Common Stock |
INSIDER POWER |
---|
36.03 |
Last 100 transactions |
Buy: 779 468 | Sell: 362 821 |
Wolumen Korelacja
Vaxcyte Inc Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vaxcyte Inc Korelacja - Waluta/Towar
Vaxcyte Inc Finanse
Annual | 2023 |
Przychody: | $0 |
Zysk brutto: | $-10.17M (0.00 %) |
EPS: | $-4.14 |
FY | 2023 |
Przychody: | $0 |
Zysk brutto: | $-10.17M (0.00 %) |
EPS: | $-4.14 |
FY | 2022 |
Przychody: | $0 |
Zysk brutto: | $-9.20M (0.00 %) |
EPS: | $-3.69 |
FY | 2021 |
Przychody: | $0.00 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-1.930 |
Financial Reports:
No articles found.
Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej